af3535 Search Results


goat anti mouse galectin 9  (R&D Systems)
91
R&D Systems goat anti mouse galectin 9
Goat Anti Mouse Galectin 9, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti mouse galectin 9/product/R&D Systems
Average 91 stars, based on 1 article reviews
goat anti mouse galectin 9 - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
anti mouse dr3  (R&D Systems)
90
R&D Systems anti mouse dr3
Galectin-9 binds to <t>DR3.</t> (a) Immunoprecipitation of recombinant human or mouse Galectin-9 with human DR3.Fc or 4-1BB.Fc. Control, human Galectin-3. (b) Immunoprecipitation of recombinant human or mouse Galectin-9 with mouse DR3.Fc. Observed molecular masses were h/m4-1BB.Fc or DR3.Fc – 50–58 kDa, m/hGalectin-9 – 36 kDa. Data in (a–b) are representative of at least three different experiments each. (c–f) Binding response of increasing concentrations (0.48–2000 nM) of hGalectin-9 (c, d) or mGalectin-9 (e, f) to immobilized hDR3.Fc (c, e) or mDR3.Fc (d, f), measured by SPR. Values represent average of three independent measurements. The response shown is reference-subtracted (unrelated Fc protein). (g–h) Human or mouse Galectin-9 or TL1A were coated onto ELISA plates and binding of WT or de-glycosylated DR3.Fc was detected using biotin anti-DR3 and streptavidin HRP. Competition was assessed with DR3.Fc first incubated with either TL1A or Galectin-9. Data are means ± s.e.m binding from triplicate cultures and representative of three different experiments.
Anti Mouse Dr3, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse dr3/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti mouse dr3 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Galectin-9 binds to DR3. (a) Immunoprecipitation of recombinant human or mouse Galectin-9 with human DR3.Fc or 4-1BB.Fc. Control, human Galectin-3. (b) Immunoprecipitation of recombinant human or mouse Galectin-9 with mouse DR3.Fc. Observed molecular masses were h/m4-1BB.Fc or DR3.Fc – 50–58 kDa, m/hGalectin-9 – 36 kDa. Data in (a–b) are representative of at least three different experiments each. (c–f) Binding response of increasing concentrations (0.48–2000 nM) of hGalectin-9 (c, d) or mGalectin-9 (e, f) to immobilized hDR3.Fc (c, e) or mDR3.Fc (d, f), measured by SPR. Values represent average of three independent measurements. The response shown is reference-subtracted (unrelated Fc protein). (g–h) Human or mouse Galectin-9 or TL1A were coated onto ELISA plates and binding of WT or de-glycosylated DR3.Fc was detected using biotin anti-DR3 and streptavidin HRP. Competition was assessed with DR3.Fc first incubated with either TL1A or Galectin-9. Data are means ± s.e.m binding from triplicate cultures and representative of three different experiments.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Treg-mediated Suppression of Inflammation Induced by DR3 Signaling is Dependent on Galectin-9

doi: 10.4049/jimmunol.1700575

Figure Lengend Snippet: Galectin-9 binds to DR3. (a) Immunoprecipitation of recombinant human or mouse Galectin-9 with human DR3.Fc or 4-1BB.Fc. Control, human Galectin-3. (b) Immunoprecipitation of recombinant human or mouse Galectin-9 with mouse DR3.Fc. Observed molecular masses were h/m4-1BB.Fc or DR3.Fc – 50–58 kDa, m/hGalectin-9 – 36 kDa. Data in (a–b) are representative of at least three different experiments each. (c–f) Binding response of increasing concentrations (0.48–2000 nM) of hGalectin-9 (c, d) or mGalectin-9 (e, f) to immobilized hDR3.Fc (c, e) or mDR3.Fc (d, f), measured by SPR. Values represent average of three independent measurements. The response shown is reference-subtracted (unrelated Fc protein). (g–h) Human or mouse Galectin-9 or TL1A were coated onto ELISA plates and binding of WT or de-glycosylated DR3.Fc was detected using biotin anti-DR3 and streptavidin HRP. Competition was assessed with DR3.Fc first incubated with either TL1A or Galectin-9. Data are means ± s.e.m binding from triplicate cultures and representative of three different experiments.

Article Snippet: After SDS-PAGE, the proteins were visualized by western blotting with anti-mouse DR3 (R&D Systems) or anti-mouse Galectin-9 (BioLegend) followed by anti-Rat IgG light chain-specific-HRP (Jackson ImmunoResearch).

Techniques: Immunoprecipitation, Recombinant, Binding Assay, Enzyme-linked Immunosorbent Assay, Incubation

Defective DR3 activity in T cells from Galectin-9−/− mice. (a) Naïve CD4+ T cells from WT or Galectin-9−/− mice were activated in vitro with anti-CD3 and anti-CD28 in the presence of control IgG and agonist TL1A.Ig. IL-2 and IFN-γ production were assessed after 48 h. (b) CD4+ T cells from WT and Galectin-9−/− mice were pre-activated with anti-CD3 and anti-CD28, and then after 48 h were restimulated with anti-CD3 in the presence of control IgG or agonist anti-DR3. IL-2 and IFN-γ production were assessed 48 h later. (c) CD4+ T cells from WT (solid line) and Galectin-9−/− (dotted line) mice were pre-activated as in (b) and stained for DR3 expression (pre-sort, left). Isotype control staining, shaded. Sorted cells were then restimulated with anti-CD3 in the presence of control IgG or agonist TL1A.Ig. IL-2 production was assessed at 24 h. All data are means ± s.e.m from triplicate cultures and representative of three different experiments. *p<0.05

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Treg-mediated Suppression of Inflammation Induced by DR3 Signaling is Dependent on Galectin-9

doi: 10.4049/jimmunol.1700575

Figure Lengend Snippet: Defective DR3 activity in T cells from Galectin-9−/− mice. (a) Naïve CD4+ T cells from WT or Galectin-9−/− mice were activated in vitro with anti-CD3 and anti-CD28 in the presence of control IgG and agonist TL1A.Ig. IL-2 and IFN-γ production were assessed after 48 h. (b) CD4+ T cells from WT and Galectin-9−/− mice were pre-activated with anti-CD3 and anti-CD28, and then after 48 h were restimulated with anti-CD3 in the presence of control IgG or agonist anti-DR3. IL-2 and IFN-γ production were assessed 48 h later. (c) CD4+ T cells from WT (solid line) and Galectin-9−/− (dotted line) mice were pre-activated as in (b) and stained for DR3 expression (pre-sort, left). Isotype control staining, shaded. Sorted cells were then restimulated with anti-CD3 in the presence of control IgG or agonist TL1A.Ig. IL-2 production was assessed at 24 h. All data are means ± s.e.m from triplicate cultures and representative of three different experiments. *p<0.05

Article Snippet: After SDS-PAGE, the proteins were visualized by western blotting with anti-mouse DR3 (R&D Systems) or anti-mouse Galectin-9 (BioLegend) followed by anti-Rat IgG light chain-specific-HRP (Jackson ImmunoResearch).

Techniques: Activity Assay, In Vitro, Staining, Expressing

Treg from Galectin-9−/− mice are refractory to stimulation through DR3. (a) CD4+Foxp3+ Treg cells from WT mice were stained for surface DR3 and intracellular Galectin-9. Shaded, isotype control. Dotted line, Treg from Galectin-9−/− mice. (b) Immunoprecipitation with TL1A.Ig or control Fc was performed on lysates from WT Treg cells. Immunoblotting was carried out with anti-DR3 (top) or anti-Galectin-9 (bottom). MW indicated. Data are representative of three experiments. (c) Treg cells from WT or Galectin-9−/− mice were stimulated with anti-CD3 and IL-2 in the presence of control IgG or agonist TL1A.Ig. Proliferation was assessed at 72 h. Data are means ± s.e.m from triplicate cultures and representative of three experiments. *Significance TL1A.Ig WT vs. Galectin-9−/−. (d) WT (solid line) and Galectin-9−/− (dotted line) Treg cells were stimulated with anti-CD3 and IL-2 in the presence of control IgG or agonist anti-DR3. After 48 h, cells were stained for intracellular IDO and IL-10. MFI indicated. Isotype controls, shaded. Data are representative of three different experiments. *p<0.05

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Treg-mediated Suppression of Inflammation Induced by DR3 Signaling is Dependent on Galectin-9

doi: 10.4049/jimmunol.1700575

Figure Lengend Snippet: Treg from Galectin-9−/− mice are refractory to stimulation through DR3. (a) CD4+Foxp3+ Treg cells from WT mice were stained for surface DR3 and intracellular Galectin-9. Shaded, isotype control. Dotted line, Treg from Galectin-9−/− mice. (b) Immunoprecipitation with TL1A.Ig or control Fc was performed on lysates from WT Treg cells. Immunoblotting was carried out with anti-DR3 (top) or anti-Galectin-9 (bottom). MW indicated. Data are representative of three experiments. (c) Treg cells from WT or Galectin-9−/− mice were stimulated with anti-CD3 and IL-2 in the presence of control IgG or agonist TL1A.Ig. Proliferation was assessed at 72 h. Data are means ± s.e.m from triplicate cultures and representative of three experiments. *Significance TL1A.Ig WT vs. Galectin-9−/−. (d) WT (solid line) and Galectin-9−/− (dotted line) Treg cells were stimulated with anti-CD3 and IL-2 in the presence of control IgG or agonist anti-DR3. After 48 h, cells were stained for intracellular IDO and IL-10. MFI indicated. Isotype controls, shaded. Data are representative of three different experiments. *p<0.05

Article Snippet: After SDS-PAGE, the proteins were visualized by western blotting with anti-mouse DR3 (R&D Systems) or anti-mouse Galectin-9 (BioLegend) followed by anti-Rat IgG light chain-specific-HRP (Jackson ImmunoResearch).

Techniques: Staining, Immunoprecipitation, Western Blot

Galectin-9 is required for suppression of EAE by anti-DR3. WT or Galectin-9−/− mice were immunized with MOG35-55 peptide and injected with either control IgG or agonist anti-DR3. (a) Percent Foxp3+CD4+ T cells in peripheral blood 5 days after the last injection of anti-DR3. (b) EAE clinical scores over time. (c) Frequencies of IL-17A+ CD4 T cells (left) and TNF+ CD4 T cells (middle and right) in draining lymph nodes on days 17 and 30, respectively. (d) Proportion of gated CD4+ cells expressing IL-10 and Foxp3 (left) and total numbers of Foxp3+IL-10+ CD4 T cells (right) in brains of anti-DR3-treated animals at day 17. (e) Proportion of gated CD4+ cells expressing IL-17 or IFN-γ (left) and total numbers of IL-17+ CD4 T cells (right) in brains of anti-DR3-treated animals at day 17. All data are either representative or means ± sem from five mice per group. Similar results in three different experiments. *p<0.05

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Treg-mediated Suppression of Inflammation Induced by DR3 Signaling is Dependent on Galectin-9

doi: 10.4049/jimmunol.1700575

Figure Lengend Snippet: Galectin-9 is required for suppression of EAE by anti-DR3. WT or Galectin-9−/− mice were immunized with MOG35-55 peptide and injected with either control IgG or agonist anti-DR3. (a) Percent Foxp3+CD4+ T cells in peripheral blood 5 days after the last injection of anti-DR3. (b) EAE clinical scores over time. (c) Frequencies of IL-17A+ CD4 T cells (left) and TNF+ CD4 T cells (middle and right) in draining lymph nodes on days 17 and 30, respectively. (d) Proportion of gated CD4+ cells expressing IL-10 and Foxp3 (left) and total numbers of Foxp3+IL-10+ CD4 T cells (right) in brains of anti-DR3-treated animals at day 17. (e) Proportion of gated CD4+ cells expressing IL-17 or IFN-γ (left) and total numbers of IL-17+ CD4 T cells (right) in brains of anti-DR3-treated animals at day 17. All data are either representative or means ± sem from five mice per group. Similar results in three different experiments. *p<0.05

Article Snippet: After SDS-PAGE, the proteins were visualized by western blotting with anti-mouse DR3 (R&D Systems) or anti-mouse Galectin-9 (BioLegend) followed by anti-Rat IgG light chain-specific-HRP (Jackson ImmunoResearch).

Techniques: Injection, Expressing

Galectin-9 is required for suppression of allergic asthma by anti-DR3. WT and Galectin-9−/− mice were immunized with OVA to induce lung inflammation, and injected with IgG or agonist anti-DR3. (a) Representative H&E staining of lung sections (left), and mean inflammation score (right). (b) Eosinophil numbers and IL-5 expression in BAL. (c) Proportion of CD4+Foxp3+ T cells in BAL (left) and draining lymph nodes (right). All results are means ± s.e.m from five mice per group, and representative of three independent experiments. *p<0.05

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Treg-mediated Suppression of Inflammation Induced by DR3 Signaling is Dependent on Galectin-9

doi: 10.4049/jimmunol.1700575

Figure Lengend Snippet: Galectin-9 is required for suppression of allergic asthma by anti-DR3. WT and Galectin-9−/− mice were immunized with OVA to induce lung inflammation, and injected with IgG or agonist anti-DR3. (a) Representative H&E staining of lung sections (left), and mean inflammation score (right). (b) Eosinophil numbers and IL-5 expression in BAL. (c) Proportion of CD4+Foxp3+ T cells in BAL (left) and draining lymph nodes (right). All results are means ± s.e.m from five mice per group, and representative of three independent experiments. *p<0.05

Article Snippet: After SDS-PAGE, the proteins were visualized by western blotting with anti-mouse DR3 (R&D Systems) or anti-mouse Galectin-9 (BioLegend) followed by anti-Rat IgG light chain-specific-HRP (Jackson ImmunoResearch).

Techniques: Injection, Staining, Expressing